Role of PI3K/AKT pathway in cancer: the framework of malignant behavior

被引：442
作者：
Jiang, Ningni [1 ,2 ,3 ]
Dai, Qijie [1 ,2 ,3 ]
Su, Xiaorui [1 ,2 ,3 ]
Fu, Jianjiang [1 ,2 ,3 ]
Feng, Xuancheng [1 ,2 ,3 ]
Peng, Juan [1 ,2 ,3 ,4 ]
机构：
[1] Guangzhou Med Univ, Dept Pathol, Affiliated Hosp 3, 63 Duobao Rd, Guangzhou 510150, Peoples R China
[2] Guangzhou Med Univ, Clin Sch 3, Guangzhou 510150, Peoples R China
[3] Guangdong Higher Educ Inst, Key Lab Reprod & Genet, Guangzhou 510150, Peoples R China
[4] Wake Forest Sch Med, Dept Microbiol & Immunol, Winston Salem, NC 27157 USA
来源：
MOLECULAR BIOLOGY REPORTS | 2020年 / 47卷 / 06期
基金：
中国国家自然科学基金;
关键词：
PI3K; AKT; PTEN; Cancer; Targeted therapy; EPITHELIAL-MESENCHYMAL TRANSITION; PROMOTES CELL-PROLIFERATION; PAPILLARY THYROID-CANCER; ACUTE MYELOID-LEUKEMIA; PROTEIN-KINASE B; RELAPSED/REFRACTORY MULTIPLE-MYELOMA; AKT INHIBITOR AFURESERTIB; HUMAN BLADDER-CANCER; PROSTATE-CANCER; SIGNALING PATHWAY;
D O I：
10.1007/s11033-020-05435-1
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Given that the PI3K/AKT pathway has manifested its compelling influence on multiple cellular process, we further review the roles of hyperactivation of PI3K/AKT pathway in various human cancers. We state the abnormalities of PI3K/AKT pathway in different cancers, which are closely related with tumorigenesis, proliferation, growth, apoptosis, invasion, metastasis, epithelial-mesenchymal transition, stem-like phenotype, immune microenvironment and drug resistance of cancer cells. In addition, we investigated the current clinical trials of inhibitors against PI3K/AKT pathway in cancers and found that the clinical efficacy of these inhibitors as monotherapy has so far been limited despite of the promising preclinical activity, which means combinations of targeted therapy may achieve better efficacies in cancers. In short, we hope to feature PI3K/AKT pathway in cancers to the clinic and bring the new promising to patients for targeted therapies.
引用
收藏
页码：4587 / 4629
页数：43
相关论文
共 400 条
  • [1] Phosphatidylinositol 3-kinase pathway activation in breast cancer brain metastases
    Adamo, Barbara
    Deal, Allison M.
    Burrows, Emily
    Geradts, Joseph
    Hamilton, Erika
    Blackwell, Kimberly L.
    Livasy, Chad
    Fritchie, Karen
    Prat, Aleix
    Harrell, J. Chuck
    Ewend, Matthew G.
    Carey, Lisa A.
    Miller, C. Ryan
    Anders, Carey K.
    [J]. BREAST CANCER RESEARCH, 2011, 13 (06)
  • [2] Exome Sequencing of Head and Neck Squamous Cell Carcinoma Reveals Inactivating Mutations in NOTCH1
    Agrawal, Nishant
    Frederick, Mitchell J.
    Pickering, Curtis R.
    Bettegowda, Chetan
    Chang, Kyle
    Li, Ryan J.
    Fakhry, Carole
    Xie, Tong-Xin
    Zhang, Jiexin
    Wang, Jing
    Zhang, Nianxiang
    El-Naggar, Adel K.
    Jasser, Samar A.
    Weinstein, John N.
    Trevino, Lisa
    Drummond, Jennifer A.
    Muzny, Donna M.
    Wu, Yuanqing
    Wood, Laura D.
    Hruban, Ralph H.
    Westra, William H.
    Koch, Wayne M.
    Califano, Joseph A.
    Gibbs, Richard A.
    Sidransky, David
    Vogelstein, Bert
    Velculescu, Victor E.
    Papadopoulos, Nickolas
    Wheeler, David A.
    Kinzler, Kenneth W.
    Myers, Jeffrey N.
    [J]. SCIENCE, 2011, 333 (6046) : 1154 - 1157
  • [3] Mechanism of activation of protein kinase B by insulin and IGF-1
    Alessi, DR
    Andjelkovic, M
    Caudwell, B
    Cron, P
    Morrice, N
    Cohen, P
    Hemmings, BA
    [J]. EMBO JOURNAL, 1996, 15 (23) : 6541 - 6551
  • [4] Mechanisms of PTEN loss in cancer: It's all about diversity
    Alvarez-Garcia, Virginia
    Tawil, Yasmine
    Wise, Helen M.
    Leslie, Nicholas R.
    [J]. SEMINARS IN CANCER BIOLOGY, 2019, 59 : 66 - 79
  • [5] Hodgkin Lymphoma: Diagnosis and Treatment
    Ansell, Stephen M.
    [J]. MAYO CLINIC PROCEEDINGS, 2015, 90 (11) : 1574 - 1583
  • [6] Epstein-Barr virus-encoded LMP1 induces ectopic CD137 expression on Hodgkin and Reed-Sternberg cells via the PI3K-AKT-mTOR pathway
    Aravinth, Sneha Priya
    Rajendran, Sakthi
    Li, Yating
    Wu, Meihui
    Wong, Anna Hiu Yi
    Schwarz, Herbert
    [J]. LEUKEMIA & LYMPHOMA, 2019, 60 (11) : 2697 - 2704
  • [7] Non-Hodgkin lymphoma
    Armitage, James O.
    Gascoyne, Randy D.
    Lunning, Matthew A.
    Cavalli, Franco
    [J]. LANCET, 2017, 390 (10091) : 298 - 310
  • [8] Understanding the interplay between the proteasome pathway and autophagy in response to dual PI3K/mTOR inhibition in myeloma cells is essential for their effective clinical application
    Aronson, L. I.
    Davenport, E. L.
    Mirabella, F.
    Morgan, G. J.
    Davies, F. E.
    [J]. LEUKEMIA, 2013, 27 (12) : 2397 - 2403
  • [9] Pancreatic cell plasticity and cancer initiation induced by oncogenic Kras is completely dependent on wild-type PI 3-kinase p110α
    Baer, Romain
    Cintas, Celia
    Dufresne, Marlene
    Cassant-Sourdy, Stephanie
    Schoenhuber, Nina
    Planque, Laetitia
    Lulka, Hubert
    Couderc, Bettina
    Bousquet, Corinne
    Garmy-Susini, Barbara
    Vanhaesebroeck, Bart
    Pyronnet, Stephane
    Saur, Dieter
    Guillermet-Guibert, Julie
    [J]. GENES & DEVELOPMENT, 2014, 28 (23) : 2621 - 2635
  • [10] Prevention of Prostate Cancer Morbidity and Mortality Primary Prevention and Early Detection
    Barry, Michael J.
    Simmons, Leigh H.
    [J]. MEDICAL CLINICS OF NORTH AMERICA, 2017, 101 (04) : 787 - +
12345678910